Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.7
3.5
Journals
Vaccines
Special Issues
Epidemiology, Vaccines and Surveillance of COVID-19
share announcement

Epidemiology, Vaccines and Surveillance of COVID-19

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "COVID-19 Vaccines and Vaccination".

Deadline for manuscript submissions: 20 March 2027 | Viewed by 1355

Editors

Dr. Chukwuma Mbaeyi

E-Mail Website
Guest Editor
Global Immunization Division, Global Health Center, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA
Interests: polio eradication; vaccines; immunization; vaccine-preventable diseases
Dr. Abdinoor Mohamed

E-Mail Website
Guest Editor
Global Immunization Division, Global Health Center, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA
Interests: polio eradication; vaccines; immunization; vaccine-preventable diseases
Dr. Nishant Kishore

E-Mail Website
Guest Editor
The Carter Center, 453 John Lewis Freedom Pkwy NE, Atlanta, GA 30307, USA
Interests: infectious disease epidemiology; mathematical modeling; digital health surveillance systems

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to this Special Issue in Vaccines on the Epidemiology, Vaccinology, and Surveillance of COVID-19. This Special Issue aims to discuss the evolving epidemiology of COVID-19, from its advent at the onset of the pandemic to the current state of affairs. It will also examine measures taken to mitigate the spread and impact of the disease, including surveillance and testing measures, as well as the impact of vaccines, including their safety, immunogenicity, efficacy, and effectiveness.

In this Special Issue, original research articles, commentaries, and reviews are welcome. Research areas may include (but are not limited to) the following: COVID-19 epidemiology, vaccinology, surveillance, and case detection and management.

We look forward to receiving your contributions.

Dr. Chukwuma Mbaeyi
Dr. Abdinoor Mohamed
Dr. Nishant Kishore
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • COVID-19
  • coronavirus
  • SARS CoV-2
  • epidemiology
  • surveillance
  • case detection
  • vaccines
  • vaccinology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

20 pages, 861 KB  
Article
Characteristics of SARS-CoV-2 Reinfection and Ancestral RBD-Blocking Antibody Levels: A Cross-Sectional Study in the Post-Zero-COVID Era from Shanghai
by Chen Chen, Yuanfei Zhu, Huiting Wang, Fei Wu, Youhua Xie, Qingqing Jia, Yang Yang, Jiangjiang Lyu, Junqiang Qu, Qiao Wang and Fan Wu
Vaccines 2026, 14(6), 520; https://doi.org/10.3390/vaccines14060520 - 10 Jun 2026
Viewed by 325
Abstract
Background: SARS-CoV-2 reinfections increased substantially after the emergence of Omicron variants. Methods: We conducted a cross-sectional study of 2095 individuals with prior Omicron BA.2 infection in Shanghai, China, during the early post-zero-COVID period. Data on demographics, infection history, and lifestyle factors [...] Read more.
Background: SARS-CoV-2 reinfections increased substantially after the emergence of Omicron variants. Methods: We conducted a cross-sectional study of 2095 individuals with prior Omicron BA.2 infection in Shanghai, China, during the early post-zero-COVID period. Data on demographics, infection history, and lifestyle factors were collected via questionnaire, and blood samples were obtained for ancestral RBD-blocking antibody measurement. Results: Meeting WHO physical activity recommendations (≥600 MET-min/week) was associated with lower reinfection odds (OR = 0.59, 95% CI: 0.46–0.74, p < 0.001). The overall median ancestral RBD-blocking antibody level was 263.93 U/mL (IQR: 36.41–331.87). Older age was associated with lower ancestral RBD-blocking antibody levels (β = –0.0038 per year, 95% bootstrap CI: –0.0057 to –0.0019, p < 0.001). All vaccinated groups had significantly higher ancestral RBD-blocking antibody levels than unvaccinated individuals: partially vaccinated (β = 0.4440, 95% CI: 0.1569 to 0.6830, p < 0.001), fully vaccinated (β = 0.8516, 95% CI: 0.7464 to 0.9595, p < 0.001), homologous booster (β = 1.0297, 95% CI: 0.9408 to 1.1223, p < 0.001), and heterologous booster (β = 1.0838, 95% CI: 0.9387 to 1.2226, p < 0.001). Time since last immune event was inversely associated with ancestral RBD-blocking antibody levels (β = –0.0232 per month, 95% CI: –0.0385 to –0.0077, p = 0.0031). Conclusions: In this cross-sectional study, meeting WHO physical activity recommendations was associated with 41% lower odds of SARS-CoV-2 reinfection, although reverse causality cannot be ruled out. All vaccinated groups had higher ancestral RBD-blocking antibody levels than unvaccinated individuals. Older age and longer time since last immune event were associated with lower ancestral RBD-blocking antibody levels. These associations need confirmation in prospective, well-powered studies. Full article
(This article belongs to the Special Issue Epidemiology, Vaccines and Surveillance of COVID-19)
►▼ Show Figures

Figure 1

Review

Jump to: Research

25 pages, 918 KB  
Review
Six Years of COVID-19: Lessons from Epidemiology, Vaccination Campaigns, Clinical Risk Stratification, and Thromboembolic Surveillance
by Carmine Siniscalchi, Egidio Imbalzano, Manuela Basaglia, Nicoletta Cerundolo, Tiziana Meschi, Beatrice Prati, Alberto Parise, Antonio Nouvenne and Pierpaolo Di Micco
Vaccines 2026, 14(7), 611; https://doi.org/10.3390/vaccines14070611 - 14 Jul 2026
Viewed by 460
Abstract
Six years after the emergence of SARS-CoV-2, COVID-19 remains a dynamic public health challenge shaped by viral evolution, heterogeneous population immunity, changing vaccine strategies, and the long-term consequences of acute infection. Although the transition from pandemic emergency to endemic circulation has reduced the [...] Read more.
Six years after the emergence of SARS-CoV-2, COVID-19 remains a dynamic public health challenge shaped by viral evolution, heterogeneous population immunity, changing vaccine strategies, and the long-term consequences of acute infection. Although the transition from pandemic emergency to endemic circulation has reduced the global burden of severe disease, COVID-19 continues to affect vulnerable populations, particularly older adults, frail patients, immunocompromised individuals, and subjects with multiple comorbidities. Vaccination has substantially modified the clinical course of infection, reducing hospitalization, intensive care admission, and mortality, while also reshaping surveillance priorities toward variant monitoring, vaccine effectiveness, waning immunity, breakthrough infections, and long COVID. At the same time, the pandemic has highlighted the need for integrated clinical risk stratification, including age, sex, frailty, inflammatory biomarkers, respiratory support requirements, and thromboembolic risk. Venous and arterial thrombotic complications have represented a key feature of severe COVID-19 and remain relevant for both acute management and post-discharge follow-up. This narrative review summarizes the main lessons learned from six years of COVID-19, focusing on epidemiology, vaccination campaigns, clinical risk assessment, thromboembolic complications, and surveillance strategies. Particular attention is given to the need for multidisciplinary and data-driven approaches capable of integrating virological, epidemiological, clinical, geriatric, and vascular medicine perspectives. Future COVID-19 surveillance should move beyond case counting and incorporate vaccine impact, population vulnerability, thrombotic and bleeding complications, long-term outcomes, and preparedness for emerging variants. Full article
(This article belongs to the Special Issue Epidemiology, Vaccines and Surveillance of COVID-19)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop